VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISHL12 2022 | The potential role of bispecifics in Hodgkin lymphoma

In this video, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, briefly discusses the role of bispecifics in Hodgkin lymphoma (HL), highlighting promising agents in the pipeline, such as AFM13, and the importance of further evaluating these agents in clinical trials. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter